Composition for preventing or treating diabetic foot disease, comprising taurodeoxycholic acid
Taurodeoxycholic acid-based compositions address the limitations of current diabetic foot ulcer treatments by promoting wound healing and preventing infection, providing a safe and effective topical solution.
Patent Information
- Application Number
- PCT/KR2026/096827
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for diabetic foot ulcers are limited by slow wound healing, risk of infection, antibiotic resistance, high cost, and lack of multifunctional agents that promote wound healing, improve blood flow, and provide neuroprotection.
A pharmaceutical composition containing taurodeoxycholic acid or its pharmaceutically acceptable salts, which can be formulated into various topical applications such as gels, ointments, and creams, promoting wound healing by enhancing collagen deposition, epithelial regeneration, and reducing inflammation, while providing antibacterial properties to prevent infection.
The composition significantly reduces wound size, accelerates healing, and prevents infection, offering a safe, convenient, and versatile treatment option for diabetic foot ulcers.
Smart Images

Figure KR2026096827_12112026_PF_FP_ABST
Abstract
Description
Composition for the prevention or treatment of diabetic foot disease containing taurodeoxycholic acid
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic foot disease comprising taurodeoxycholic acid (TDCA), and more specifically, to a pharmaceutical composition for the prevention or treatment of diabetic foot disease, preferably diabetic foot ulcer, comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and to a topical skin preparation comprising the same.
[0002]
[0003] Diabetic foot disease is a collective term for neuropathy, structural deformities, calluses, changes in the skin and nails, foot ulcers, infections, and vascular diseases that occur in the feet of patients with diabetes; diabetic foot ulcers (DFU) are the most representative condition. They occur when the skin or mucous membranes of the feet become eroded, and they are one of the common complications in diabetic patients. Due to reduced blood flow and impaired wound healing ability caused by impaired blood sugar control, ulcers do not heal well and easily worsen.
[0004] It is known that approximately 15–25% of patients with diabetes will experience at least one diabetic foot ulcer during their lifetime. This not only significantly reduces the patient's quality of life but also leads to serious problems that can result in infection, osteomyelitis, or even death. While various methods such as wound dressings, antibiotic use, blood flow improvement, and the application of growth factors have been attempted to treat diabetic foot ulcers, these treatments have the following limitations:
[0005] 1) Delay in wound healing: Existing treatments have limitations in promoting wound healing, and the healing process is very slow, especially in the case of chronic ulcers.
[0006] 2) Risk of infection: There is a risk of antibiotic resistance and side effects when using antibiotics.
[0007] 3) Cost and convenience: The use of expensive treatments and frequent hospital visits may place a burden on patients.
[0008] 4) Limitations of neuroprotection and blood flow improvement: There is a lack of treatments that simultaneously provide blood flow improvement and neuroprotective effects.
[0009] Accordingly, there is a continuing need for the development of new pharmaceutical compositions that are effective, safe, and convenient to use. In particular, there is a demand for multifunctional therapeutic agents that can promote wound healing, improve blood flow, and prevent infection.
[0010]
[0011] Against this technical background, the inventors present a novel composition effective for treating diabetic foot diseases, particularly diabetic foot ulcers, thereby presenting an innovative turning point in the field of foot disease treatment and contributing to the acceleration of wound healing and the reduction of medical burden for patients.
[0012]
[0013] The information described above in the background section is intended solely to enhance understanding of the background of the present invention and may not include information that forms prior art already known to those skilled in the art to which the present invention belongs.
[0014]
[0015] [Prior Art Literature]
[0016] [Patent Literature]
[0017] Korean Registered Patent No. 2,204,406
[0018] Korean Patent Publication No. 2023-0116485
[0019] Chinese Public Patent No. 114432462A
[0020]
[0021] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diabetic foot disease comprising taurodeoxycholic acid.
[0022] Another objective of the present invention is to provide a method for preventing or treating diabetic foot disease using taurodeoxycholic acid, the use of taurodeoxycholic acid for the prevention or treatment of diabetic foot disease, and the use of taurodeoxycholic acid for the manufacture of a drug for the prevention or treatment of diabetic foot disease.
[0023] Another objective of the present invention is to provide a topical skin preparation for the prevention or treatment of diabetic foot disease comprising the above pharmaceutical composition.
[0024] Another objective of the present invention is to provide a food composition and a cosmetic composition for preventing or improving diabetic foot disease comprising taurodeoxycholic acid.
[0025]
[0026] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of diabetic foot disease comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[0027] The present invention also provides a method for preventing or treating diabetic foot disease comprising the step of administering taurodeoxycholic acid or a pharmaceutically acceptable salt thereof.
[0028] The present invention also provides the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of diabetic foot disease.
[0029] The present invention also provides the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the manufacture of a drug for the prevention or treatment of diabetic foot disease.
[0030] The present invention also provides a topical skin preparation for the prevention or treatment of diabetic foot disease comprising the above pharmaceutical composition.
[0031] The present invention also provides a food composition and a cosmetic composition for preventing or improving diabetic foot disease, comprising taurodeoxycholic acid or a salt thereof as an active ingredient.
[0032]
[0033] As a result of applying the composition according to the present invention to an animal model of diabetic foot ulcers, it was confirmed that the wound size was significantly reduced and that it has a direct wound healing promoting effect. It was also confirmed that the composition according to the present invention has effects such as increased collagen deposition and promotion of epithelial regeneration, reduction of inflammatory response through inhibition of p-IκBα and p-NFκB pathways, inhibition of NLRP3 inflammasome activity (NLRP3 / ASC, NLRP3 / Caspase-1), regulation of TGF-β1 and PDGF-mediated wound healing and ECM remodeling, inhibition of ECM degrading enzymes MMP-1, MMP-2, and MMP-9, and normalization of the ECM degradation-generation balance in DFU wounds through the restoration of MMP inhibitors TIMP-3 and TIMP-1 expression. Furthermore, infection prevention effects through the anti-inflammatory and antibacterial properties of TDCA and a relatively safe drug profile through verified safety can be expected. Furthermore, the composition according to the present invention can be manufactured into various formulations such as gels, ointments, and creams, making it highly versatile and easy to use, which can contribute to improving the overall therapeutic effect.
[0034]
[0035] Figure 1 shows the effect of topical application of taurodeoxycholic acid (TDCA) promoting wound contraction in a mouse model of diabetic foot ulcer (DFU) induced by streptozotocin (STZ) and a high-fat diet (HFD). Figure 1A shows representative macroscopic images on days 0, 4, 6, and 10 after wound induction in normal control mice treated with HA and DFU mice treated with HA, 0.5% TDCA, 1% TDCA, or EGF. Figure 1B shows the progress of wound contraction from day 0 to day 10, calculated as the reduction rate of wound area relative to the wound area on day 0. Figures 1C to E show the results of quantifying the wound contraction rates on days 4, 6, and 10, respectively. Data were expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's least significant difference (LSD) post-hoc test.
[0036] Figure 2 illustrates the effect of topical application of TDCA in promoting collagen deposition and epithelial regeneration in STZ and HFD-induced DFU mouse models. Figure 2A shows Masson's trichrome staining images of wound tissue collected on day 10 after wound induction, where blue staining indicates collagen fibers. Figure 2B shows the results of quantifying collagen density (area %) as a percentage relative to the DFU + HA group. Figure 2C shows representative immunohistochemical staining images confirming epithelial regeneration at the wound margins in each treatment group. Figure 2D shows the results of quantifying the non-re-epithelialization length at the wound margins. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0037] Figure 3 shows the effect of topical application of TDCA on inhibiting p-IκBα expression in STZ and HFD-induced DFU mouse models. Figure 3A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and p-IκBα antibodies. Figure 3B shows the results of quantifying p-IκBα fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0038] Figure 4 shows the effect of topical application of TDCA on inhibiting p-NF-κB activation in STZ and HFD-induced DFU mouse models. Figure 4A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and p-NF-κB antibodies. Figure 4B shows the results of quantifying p-NF-κB fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0039] Figure 5 shows the effect of topical application of TDCA on inhibiting NLRP3-ASC inflammasome activation in STZ and HFD-induced DFU mouse models. Figure 5A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI, NLRP3 antibody, and ASC antibody; the co-locations of NLRP3 and ASC are indicated by yellow fluorescence in the merged image. Figure 5B shows the results of quantifying the NLRP3-ASC co-location fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0040] Figure 6 shows the effect of topical application of TDCA on inhibiting NLRP3-caspase-1 inflammasome activation in STZ and HFD-induced DFU mouse models. Figure 6A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI, NLRP3 antibody, and caspase-1 antibody; the co-locations of NLRP3 and caspase-1 are indicated by yellow fluorescence in the merged images. Figure 6B shows the results of quantifying the NLRP3-caspase-1 co-location fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0041] Figure 7 shows the effects of topical application of TDCA on the expression of TGF-β1, a factor related to wound healing and extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 7A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and TGF-β1 antibodies. Figure 7B shows the results of quantifying the TGF-β1 fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0042] Figure 8 shows the effects of topical application of TDCA on the expression of PDGF-BB, a factor related to wound healing and extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 8A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and PDGF-BB antibodies. Figure 8B shows the results of quantifying PDGF-BB fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0043] Figure 9 shows the effect of topical application of TDCA on the expression of MMP-1, a factor related to extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 9A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and MMP-1 antibodies. Figure 9B shows the results of quantifying the MMP-1 fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0044] Figure 10 shows the effect of topical application of TDCA on the expression of MMP-2, a factor related to extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 10A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and MMP-2 antibodies. Figure 10B shows the results of quantifying the MMP-2 fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0045] Figure 11 shows the effect of topical application of TDCA on the expression of MMP-9, a factor related to extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 11A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and MMP-9 antibodies. Figure 11B shows the results of quantifying the MMP-9 fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0046] Figure 12 shows the effect of topical application of TDCA on the expression of TIMP-3, a factor related to extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 12A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and TIMP-3 antibodies. Figure 12B shows the results of quantifying the TIMP-3 fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0047] Figure 13 shows the effect of topical application of TDCA on the expression of TIMP-1, a factor related to extracellular matrix remodeling, in STZ and HFD-induced DFU mouse models. Figure 13A shows representative immunofluorescence images of wound tissue sections collected on day 10 after wound induction, stained with DAPI and TIMP-1 antibodies. Figure 13B shows the results of quantifying the TIMP-1 fluorescence intensity in the wound tissue as a percentage relative to the DFU + HA group. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0048] Figure 14 shows the effect of topical application of TDCA on reducing pro-inflammatory cytokine levels in wound skin tissues of STZ and HFD-induced DFU mouse models. Figure 14A shows the results of measuring IL-1β concentrations in skin tissues on day 10 after wound induction in DFU mice treated with HA, 0.5% TDCA, 1% TDCA, or EGF. Figure 14B shows the results of measuring IL-18 concentrations in skin tissues in the same treatment groups. Data are expressed as mean ± SEM, and statistical analysis was performed using one-way ANOVA and Fisher's LSD post-hoc test.
[0049]
[0050] Specific details for implementing the invention
[0051] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.
[0052]
[0053] In one embodiment of the present invention, a composition containing taurodeoxycholic acid (TDCA) as an active ingredient was applied to an animal model of diabetic foot ulcer (DFU). As a result, it was confirmed that the wound size was significantly reduced compared to the control group, thereby confirming the direct wound healing promoting ability and the dose-dependent effect of TDCA.
[0054] Meanwhile, by utilizing the anti-inflammatory and antibacterial properties of TDCA, the risk of infection at the wound site can be reduced, contributing to a decrease in the risk of antibiotic resistance and side effects associated with antibiotic use, and improving the safety of wound management. Furthermore, TDCA and its pharmaceutically acceptable salt, HA gel, are substances with already verified safety, allowing for the expectation of a relatively safe drug profile for human application. Moreover, as they can be manufactured into various formulations such as ointments, creams, and gels, they offer high clinical utility and can be flexibly applied to various wound types. Since they are easy to use and do not cause significant inconvenience to patients' daily lives, they can contribute to improving treatment continuity and overall therapeutic efficacy, and serve as a factor in increasing patient satisfaction.
[0055] In summary, the composition according to the present invention is formulated in a form that can be directly applied to a wound site, thereby enhancing convenience and treatment efficiency compared to existing treatments, accelerating wound healing, and providing an infection prevention effect, thus presenting a new alternative for the treatment of diabetic foot disease.
[0056]
[0057] Accordingly, in one aspect, the present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic foot disease comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[0058] In another aspect, the present invention relates to a method for preventing or treating diabetic foot disease comprising the step of administering taurodeoxycholic acid or a pharmaceutically acceptable salt thereof.
[0059] In another aspect, the present invention relates to the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of diabetic foot disease.
[0060] In another aspect, the present invention relates to the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the manufacture of a drug for the prevention or treatment of diabetic foot disease.
[0061] The term “prevention” as used in the present invention refers to any act of preventing the onset of diabetic foot disease or delaying its progression through the administration of the above composition. Furthermore, the term “treatment” as used in the present invention refers to any act of improving, alleviating, or completely curing the symptoms of diabetic foot disease through the administration of the above composition.
[0062]
[0063] In the present invention, the taurodeoxycholic acid (TDCA) is a type of bile acid, in the form of taurine-conjugated deoxycholic acid, and has a chemical structure represented by [Chemical Formula 1] below, and more specifically, has a chemical structure represented by [Chemical Formula 2] below.
[0064]
[0065] [Chemical Formula 1]
[0066]
[0067] [Chemical Formula 2]
[0068]
[0069] In the present invention, the taurodeoxycholic acid may be used as it is isolated from animals, such as humans, cattle, pigs, sheep, dogs, goats, or rabbits, is commercially available, or is synthesized.
[0070]
[0071] In the present invention, the composition comprises taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as the pharmaceutically acceptable salt. Inorganic acids and organic acids may be used as free acids; hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used as inorganic acids, and citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, emvonic acid, glutamic acid, aspartic acid, etc. may be used as organic acids. Preferably, the salt may be characterized as being one or more salts selected from the group consisting of hydrochloride, sulfate, phosphate, mesylate, malate, maleate, mesylate, besylate, hydrogen sulfate, oxalate, fumarate, tartarate, citrate, succinate, and acetate, but is not limited thereto, and is designed to function stably in the body.
[0072] The taurodeoxycholic acid according to the present invention comprises not only pharmaceutically acceptable salts but also all salts, stereoisomers, hydrates, and solvates that can be prepared by conventional methods.
[0073] In the present invention, the composition may be characterized by further comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, but is not limited thereto.
[0074]
[0075] In the present invention, the composition may additionally comprise a suitable pharmaceutically acceptable carrier, excipient, or diluent according to conventional methods. The term “pharmaceutically acceptable” means a substance that is physiologically acceptable and, when administered to humans, does not typically cause allergic reactions such as gastrointestinal disorders or dizziness, or similar reactions. Carriers, excipients, and diluents that may be included in a composition containing a compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0076] When formulating the composition of the present invention, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and these solid dosage forms are prepared by mixing at least one excipient with the above compounds, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may include various excipients, for example, wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 60, cocoa paste, laurin paste, glycerogelatin, etc. may be used.
[0077] The composition containing taurodeoxycholic acid of the present invention may have a formulation selected from the group consisting of tablets, capsules, injections, lozenges, powders, pills, granules, liquids, suspensions, oral liquids, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, lyophilized suppositories, and vaginal tablets according to conventional methods, but is not limited thereto, and can be formulated into an appropriate formulation as needed.
[0078] The composition according to the present invention can be formulated into a skin delivery formulation according to standard pharmaceutical practices and can maximize the therapeutic effect by applying it directly to a wound site to act locally. These formulations may contain, in addition to the active ingredient, additives such as carriers, excipients, adjuvants, or diluents that are pharmaceutically acceptable and suitable for formulations that can be applied to the skin.
[0079] Preferably, the composition according to the present invention may be formulated in the form of an aqueous solution, gel, ointment, cream, lotion, paste, smear, or patch. If necessary, it may also be developed in the form of an injectable.
[0080]
[0081] In the present invention, the term "administration" means providing a specific substance to a patient by any suitable method, and the route of administration of the composition of the present invention may be oral or parenteral (e.g., intravenously, subcutaneously, intraperitoneally, or topically) through any general route capable of reaching the target tissue. Additionally, the composition may be administered by any device capable of delivering the active substance to target cells.
[0082] The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by taking all of the above-mentioned factors into account, and this can be easily determined by a person skilled in the art.
[0083] Specifically, the effective amount of the compound according to the present invention may vary depending on the patient's age, gender, and weight, and may be administered daily or every other day, or divided into 1 to 3 doses per day. However, since the dosage may be increased or decreased depending on the route of administration, severity, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
[0084]
[0085] In the present invention, the diabetic foot disease may be characterized as being selected from the group consisting of athlete's foot, fungal infection, callus, corn, blister, bunion, dry skin, hammertoe, ingrown toenail, plantar wart, diabetic foot edema, diabetic foot pain, and diabetic foot ulcer.
[0086] Preferably, the above diabetic foot disease may be characterized as a diabetic foot ulcer, but is not limited thereto.
[0087]
[0088] In another aspect, the present invention relates to a topical skin preparation for the prevention or treatment of diabetic foot disease comprising the above pharmaceutical composition.
[0089] The external skin preparation according to the present invention may preferably be characterized as being any one selected from the group consisting of aqueous liquids, gels, ointments, creams, lotions, pastes, smears, and patches, but is not limited thereto.
[0090] The ingredients included in the topical skin preparation according to the present invention may include ingredients commonly used in topical skin preparations in addition to the active ingredient, such as, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, and carriers.
[0091] The external formulation of the present invention may be prepared in any formulation conventionally manufactured in the art, for example, as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream, and spray, but is not limited thereto. More specifically, it may be prepared in the form of a softening lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
[0092] In the case where the external agent of the present invention is a paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component.
[0093] In the case where the external agent of the present invention is a solution or an emulsion, a solvent, a solubilizing agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.
[0094] In the case where the external agent of the present invention is a suspension, liquid diluents such as water, ethanol, or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanth may be used as carrier components.
[0095] In the case where the external agent of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.
[0096] In the case where the external formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethane-5-olamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester, etc. may be used as a carrier component.
[0097]
[0098] In the present invention, the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof may be characterized by being included in each formulation in an amount of 0.03 mg / ml to 10 mg / ml, but is not limited thereto. Preferably, it may be characterized by being included in an amount of 0.05 mg / ml to 8 mg / ml, more preferably 0.1 mg / ml to 6 mg / ml, and most preferably 0.1 mg / ml to 4 mg / ml, but is not limited thereto.
[0099]
[0100] In another aspect, the present invention relates to a food composition for preventing or improving diabetic foot disease comprising taurodeoxycholic acid or a food-grade acceptable salt thereof as an active ingredient.
[0101] The term “improvement” in the present invention refers to any act that at least reduces parameters related to the state of a disease being treated by the administration (or application) of the above composition, such as the degree of symptoms.
[0102] In the present invention, the terms food composition, health functional food composition, or health functional food are used interchangeably.
[0103] The food composition of the present invention can be used in various ways, such as in pharmaceuticals, foods, and beverages for preventing oxidation. The health functional food of the present invention includes, for example, various types of food, candy, chocolate, beverages, gum, tea, vitamin complexes, health supplements, etc., and can be used in the form of powder, granules, tablets, capsules, or beverages.
[0104] The pharmaceutical composition of the present invention may be added to food or beverages for the purpose of preventing or improving diabetic foot disease.
[0105] The health beverage composition of the present invention has no particular limitations on the liquid components other than containing the extract as an essential component in the indicated proportion, and may contain various flavoring agents or natural carbohydrates as additional components, as in conventional beverages. Examples of the natural carbohydrates mentioned above include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 ml of the composition of the present invention.
[0106] The composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the compositions of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not particularly important, it is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
[0107]
[0108] In another aspect, the present invention relates to a cosmetic composition for preventing or improving diabetic foot disease comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[0109] The taurodeoxycholic acid of the present invention or a pharmaceutically acceptable salt thereof forms a cosmetic composition together with a substance useful for cosmetics. The substance useful for cosmetics includes, but is not limited to, antioxidants, binders, bulking agents, chelating agents, colorants, emollients, emulsion stabilizers, film-forming agents, fillers, fragrance components, gelling agents, hair conditioners, hair fixatives, humectants, plasticizers, preservatives, skin conditioners, solvents, sunscreens, surfactants, UV absorbers, viscosity modifiers, waxes, etc. Various substances useful for cosmetics can be found in the CTFS Cosmetic Ingredient Handbook, JM Nikitakis, Ed., 1st Edition, pp. 51-101 (1988), all of which are disclosed herein incorporated herein by reference.
[0110] Depending on the function, the cosmetic composition of the present invention may be provided in various forms such as a solution (lotion-type composition), a concentrated solution, a gel, an ointment, an emulsion (cream, emulsion), a vesicle dispersion, a powder, a dense powder, a paste, or a solid. More specifically, the cosmetic composition of the present invention may be dispersed in various forms such as blush, cream (face cream, hand cream, moisturizing cream, sunscreen), cream powder, eyeliner, eyeshadow, eyebrow pencil, foundation, lotion, mascara, microemulsion, ointment, pomade, and lipstick, but is not limited thereto. These may be packaged in a compression pack containing a propellant that can be applied in the form of a foam or a spray.
[0111]
[0112] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0113]
[0114] Example 1: Preparation of a Diabetic Foot Ulcer (DFU) Animal Model and Administration of Taurodeoxycholic Acid (TDCA)
[0115] [Preparation of Experimental Animals]:
[0116] The animals used to create the diabetic foot ulcer model were 6-week-old male C57BL / 6N mice (body weight 20–25 g) purchased from SAMTAKO (Osan-si, Korea). During the experiment, feed and water were provided to the animals without restriction, and the experimental environment was maintained at a temperature of 23±3℃, a relative humidity of 50±10%, and a 12-hour light-dark cycle. All experiments were conducted in accordance with the standard guidelines of the Laboratory Animal Resource Management Center at Seoul National University and were approved by the Animal Ethics Committee.
[0117] [Animal model of diabetes induction]
[0118] Six-week-old male C57BL / 6N mice were purchased from SAMTAKO (Osan-si, Korea) and used in the experiment. After acclimatizing the mice to a standard diet for one week, they were fed a high-fat diet (D12451; 45% kcal, hereinafter HFD) for four weeks. Subsequently, diabetes was induced for one week by intraperitoneal injection of 50 mg / kg of Streptozotocin (MCE) once daily. The normal control group was prepared by feeding the high-fat diet for four weeks, followed by intraperitoneal injection of 50 mg / kg of 0.1M Citrate buffer (pH 4.5) once daily for one week. Blood glucose levels were measured after two weeks to confirm the induction of diabetes; as a result, the normal control group had blood glucose levels of 150-170 mg / dl, while the diabetes-induced animal model maintained levels above 350 mg / dl.
[0119] [Method of Administering Taurodeoxycholic Acid (TDCA) in a Diabetic Wound Animal Model]
[0120] Five normal control mice and 32 diabetes-induced animal models were prepared. After removing the hair from the dorsal area of the mice, identical circular wounds with a diameter of 4 mm were created on each mouse. The normal control group was treated with a hyaluronic acid excipient solution (Tween 80 (0.5 mg), hyaluronic acid (10 mg), 3' distilled water (1 mL)) at a dose of 20 µl once daily for 10 days. The same hyaluronic acid excipient solution was also applied to the negative control group at a dose of 20 µl once daily for 10 days. The experimental group was treated with a diabetic wound healing composition (NuDifin 0.5%, 1%) and a control drug (EGF, 0.005%) at a dose of 25 µl once daily for 10 days. The wound areas of the animals were photographed on days 0, 4, 6, and 10 to measure the area. After the experiment, the mice were euthanized with carbon dioxide, and tissue samples were collected from the wound sites to observe their histological structure. The size of the wound site was quantified using standard image analysis software (ImageJ).
[0121] The animals were divided into five groups as shown in Table 1 below to conduct the experiment:
[0122]
[0123] All groups (G1–G5) were wounded by piercing the backs of the animals as in a known diabetic foot disease model (see Int. Wound J., Vol.20, No.10, pp4394–4409, 2023 and The Lancet, Vol.98, pp1–10, 2023, etc.), and fasting blood glucose was measured after maintaining a fasting state from 9:00 AM to 3:00 PM (6 hours).
[0124]
[0125] Example 2: Confirmation of changes in wound size following TDCA administration in a DFU animal model
[0126] Wounds were induced in the animal groups (G1 to G5) of Example 1, and the degree of wound healing was checked after 10 days. Figure 1 is a graph showing this quantitatively.
[0127] As a result of the experiment, the TDCA-treated groups (G3~4) showed a statistically significant reduction in wound size compared to the normal control group (G1) and the HA-treated control group (G2), and a favorable trend in wound healing was also confirmed when compared to the EGF-treated group (G5) (Fig. 1). In particular, the group treated with 1% TDCA showed a faster wound healing speed and a higher healing rate, suggesting that the composition of the present invention is effective in treating diabetic foot disease.
[0128] The above wound healing degree (Percent of wound contraction, %) was calculated using Equation 1 below.
[0129] [Equation 1]
[0130] Percent of wound contraction (%) = [Initial wound area on Day 0 - Wound area measured at each time point] / [Initial wound area on Day 0] × 100
[0131]
[0132] Example 3: Confirmation of increased collagen deposition and epithelial regeneration-promoting effects following TDCA administration in a DFU animal model
[0133] To evaluate the degree of epithelial regeneration and collagen deposition during the wound healing process, wound tissues were collected from each group on day 10 after wound induction. The collected tissues were fixed in 10% neutral buffered formalin (NBF), embedded in paraffin according to conventional methods, and serial sections were prepared using a microtome.
[0134] Masson's trichrome staining to confirm collagen deposition was performed using a Trichrome staining kit (connective tissue staining kit, Abcam) according to the manufacturer's instructions. After capturing a microscopic image including the wound site, the image was selected by setting a color threshold in ImageJ software to select a collagen-positive area stained blue, and the collagen-positive area within the wound site was measured. The calculated collagen-positive area was expressed by converting the value of each experimental group into a relative collagen density (%) compared to the HA-treated control group (DFU + HA), using the average collagen-positive area of the HA-treated control group (DFU + HA) measured at the same time point as the reference (100%), and Figure 2A is a graph showing this quantitatively.
[0135] To evaluate the degree of epithelial regeneration by visualizing the regenerating epidermis staining brown in keratinized epithelium, immunohistochemical staining was performed on wound sections using an anti-cytokeratin 10 antibody (NBP3-16460, Novus, 1:800 dilution) according to the manufacturer's instructions. The final evaluation variable was defined as the length (μm) of the section along the wound margin where epithelial regeneration did not occur, and the length of the wound margin where continuous cytokeratin 10-positive epithelium was not observed was quantified using the linear measurement function of ImageJ software. In this case, a shorter length of the remaining negative section was considered to indicate better epithelial regeneration, and Figure 2B is a graph showing this quantitatively.
[0136] Experimental results showed that when evaluating the degree of collagen deposition using the Mason tricolor staining method, the HA-treated control group (G2) exhibited limited extracellular matrix formation and reduced collagen deposition, whereas the normal control group (G1) showed sufficient collagen deposition in the wound area. In the TDCA-treated groups (G3, G4), collagen deposition increased in a dose-dependent manner, confirming significant collagen accumulation compared to the HA-treated control group (G2), and the EGF-treated group (G5) also increased collagen deposition, but the degree did not reach the level observed in the 1% TDCA-treated group (G4) (Fig. 2A). These results suggest that the TDCA-containing composition of the present invention can be effectively used to promote extracellular matrix and collagen regeneration in diabetic chronic wounds, such as diabetic foot disease.
[0137] In addition, in the re-epithelialization analysis using cytokeratin 10 immunohistochemistry, it was confirmed that a significant length of unhealed wound remained along the wound margins in the HA-treated control group (G2). In contrast, the length of the unhealed wound was significantly shorter in the normal control group (G1), and the length of the unhealed lesion decreased in a concentration-dependent manner in the TDCA-treated groups (G3, G4). Among these, the 1% TDCA-treated group (G4) showed a reduction in the length of the unhealed wound that approached the level of the normal control group (G1). The EGF-treated group (G5) also showed an effect of improving epithelial closure, but the effect of reducing the length of the unhealed wound was found to be somewhat lower compared to the 1% TDCA-treated group (G4) (Fig. 2B).
[0138] From these results, it is suggested that the TDCA-containing composition of the present invention can be effectively used to promote re-epithelialization and improve wound closure in chronic diabetic wounds, such as diabetic foot disease.
[0139]
[0140] Example 4: Confirmation of the effect of reducing inflammatory response through inhibition of H&E and inflammatory markers p-IκBα and p-NFκB pathways following TDCA administration in a DFU animal model
[0141] To evaluate IκBα and NFκB signaling activation at the wound site, immunofluorescence staining was performed on prepared wound sections using an anti-p IκBα antibody (ab133462, Abcam; 1:200, rabbit) or a p NFκB antibody (CST 3303, Cell Signaling; 1:100, rabbit) as the primary antibody. Subsequently, an Alexa Fluor 546 conjugated anti-rabbit secondary antibody (A10040; 1:100) was applied, and cell nuclei were counterstained using DAPI.
[0142] The mean fluorescence intensity (MFI) within the wound area was calculated using ImageJ software. The region corresponding to p IκBα or p NF κB among the red fluorescent signals stained with Alexa Fluor 546 was set as the ROI, and the MFI value of each segment was normalized as a percentage (%) relative to the mean value of the HA-treated control group (DFU + HA) to evaluate the difference between groups; Figures 3 and 4 are graphs showing this quantitatively.
[0143] As a result of the experiment, in the HA-treated control group (G2), an enhancement of inflammatory signaling was observed, characterized by increased phosphorylation of IκBα and p NF κB. The TDCA-treated groups (G3, G4) reduced the expression of these indicators in a concentration-dependent manner, and even in the normal control group (G1), p IκBα levels were lower compared to the HA-treated control group (G2). In particular, in the TDCA-treated groups (G3, G4), the expression of p IκBα and p NF κB was significantly reduced, indicating that inflammatory signaling was effectively suppressed. The EGF-treated group (G5) also reduced p IκBα and p NF κB levels, but the inhibitory effect was lower than that of the 1% TDCA-treated group (G4). The reduction effect observed in each treatment group compared to the HA-treated control group (G2) showed a statistically significant difference (p < 0.001; Figs. 3 and 4), and these results suggest that the TDCA-containing composition of the present invention can be effectively used to promote wound healing in diabetic chronic wounds, such as diabetic foot disease, through the regulation of the p IκBα and p NF κB pathways.
[0144]
[0145] Example 5: Confirmation of the inhibitory effect of TDCA administration on NLRP3 inflammasome activity in a DFU animal model
[0146] To evaluate the degree of inflammasome activity during the wound healing process, double immunofluorescence staining was performed on prepared wound sections using NLRP3 (MA5-32255, Invitrogen; 1:100, rabbit), ASC (sc 514414, Santa Cruz; 1:50, mouse), and caspase 1 (sc 56036, Santa Cruz; 1:50, mouse) as primary antibodies. Subsequently, Alexa Fluor 546 anti-rabbit secondary antibody (A10040; 1:100) and Alexa Fluor 488 anti-mouse secondary antibody (A21202; 1:100) were sequentially treated, and the nuclei were counterstained using DAPI.
[0147] Mean fluorescence intensity (MFI) was calculated as a quantitative indicator of NLRP3 inflammasome activity, and the MFI value of each group was expressed as a percentage (%) relative to the HA-treated control group (DFU + HA). Co-expression of NLRP3 and ASC or NLRP3 and caspase 1 was evaluated using dual immunofluorescence imaging. NLRP3 was visualized as green fluorescence using an Alexa Fluor 488 conjugated secondary antibody, and ASC or caspase 1 as red fluorescence using an Alexa Fluor 546 conjugated secondary antibody. The co-expression area, where green (NLRP3) and red (ASC or caspase 1) fluorescence overlapped to appear yellow within the wound site, was quantified using ImageJ. The MFI of the measured yellow co-expression signal was normalized as a percentage (%) relative to the mean value of the HA-treated control group (DFU + HA) to evaluate the difference between groups, and Figures 5 and 6 are graphs showing this quantitatively.
[0148] As a result of the experiment, inflammasome activation was enhanced in the wounds of the HA-treated control group (G2), with an increased co-expression of NLRP3+ASC and NLRP3+Caspase 1. In the normal control group (G1), the co-expression levels of NLRP3+ASC ASC and NLRP3+Caspase 1 were significantly lower compared to the HA-treated control group (G2). In the TDCA-treated groups (G3, G4), both indicators decreased in a concentration-dependent manner, resulting in significantly lower co-expression of NLRP3+ASC ASC and NLRP3+Caspase 1 compared to the HA-treated control group (G2). Additionally, a decrease in the co-expression of NLRP3+ASC ASC and NLRP3+Caspase 1 was observed in the EGF-treated group (G5), but the inhibitory effect was lower than that of the 1% TDCA-treated group (G4) (Figs. 5 and 6).
[0149] From these results, it is suggested that the TDCA-containing composition of the present invention can be effectively used to regulate inflammatory responses and promote wound healing by inhibiting NLRP3 inflammasome activation in a diabetic foot ulcer model.
[0150]
[0151] Example 6: Confirmation of the regulatory effects of TDCA administration on TGF-β1 and PDGF-mediated wound healing and ECM remodeling in a DFU animal model
[0152] To evaluate the expression of wound healing-related growth factors, immunofluorescence staining was performed on prepared wound sections using an anti-TGF β1 antibody (orb221933, Biorbyt; 1:100, rabbit) or an anti-PDGF BB antibody (bs 0424R, Bioss; 1:200, rabbit) as the primary antibody, followed by the application of an Alexa Fluor 546 conjugated anti-rabbit secondary antibody (A10040; 1:100), and then the cell nuclei were counterstained with DAPI.
[0153] The expression levels of TGF β1 and PDGF were calculated as the mean fluorescence intensity (MFI) within the wound site using ImageJ software. The region corresponding to TGF β1 or PDGF BB among the red fluorescent signals stained with Alexa Fluor 546 was set as the ROI, and the MFI value of each section was normalized as a percentage (%) relative to the mean value of the HA-treated control group (DFU + HA) to evaluate the difference between groups. Figures 7 and 8 are graphs showing this quantitatively.
[0154] As a result of the experiment, TGF β1 levels in the normal control group (G1) were lower than those in the HA-treated control group (G2), and the TDCA-treated groups (G3, G4) reduced TGF β1 expression in a concentration-dependent manner, showing a significant decrease compared to the HA-treated control group (G2). The EGF-treated group (G5) also reduced TGF β1, showing an inhibitory effect similar to that of the 0.5% TDCA-treated group (G3), but did not reach the level of inhibition observed in the 1% TDCA-treated group (G4). All of these TGF β1 reduction effects were statistically significant compared to the HA-treated control group (G2) (p < 0.001, Fig. 7).
[0155] In addition, PDGF BB expression in the normal control group (G1) was higher than that of the HA-treated control group (G2), and in the TDCA-treated groups (G3, G4), a significant increase in PDGF BB levels was observed compared to the HA-treated control group (G2). The EGF-treated group (G5) also showed increased PDGF BB expression compared to the HA-treated control group (G2), but the effect was lower than that of the 1% TDCA-treated group (G4) (Fig. 8).
[0156] From these results, it is suggested that the TDCA-containing composition of the present invention can be effectively used to improve the inflammatory and tissue regeneration environment and promote wound healing through the regulation of TGF β1 and PDGF signaling in a diabetic foot ulcer model.
[0157]
[0158] Example 7: Confirmation of the inhibitory effect of TDCA administration on ECM degrading enzymes MMP-1, MMP-2, and MMP-9 in a DFU animal model
[0159] To evaluate the expression of MMPs, which are ECM-degrading enzymes in the wound site, immunofluorescence staining was performed on prepared wound sections using anti-MMP 1 (bs 4599R, Bioss; 1:100, rabbit), anti-MMP 2 (bs 1316R, Bioss; 1:200, rabbit), or anti-MMP 9 (ab283575, Abcam; 1:200, rabbit) as primary antibodies. Subsequently, Alexa Fluor 546 conjugated anti-rabbit secondary antibody (A10040; 1:100) was applied, and the nuclei were counterstained with DAPI.
[0160] The expression levels of MMP 1, MMP 2, and MMP 9 were quantified as mean fluorescence intensity (MFI) within the wound site using ImageJ software. Regions corresponding to MMP 1, MMP 2, or MMP 9 among the red fluorescent signals stained with Alexa Fluor 546 were set as ROIs, and the MFI values of each section were normalized as a percentage (%) relative to the mean value of the HA-treated control group (DFU + HA) to evaluate the differences between groups. Figures 9, 10, and 11 are graphs showing this quantitatively.
[0161] As a result of the experiment, the expression of substrate remodeling enzymes MMP1 and MMP2 in the HA-treated control group (G2) was significantly increased compared to the normal control group (G1). In the TDCA-treated groups (G3, G4), a significant decrease in the expression of both MMP1 and MMP2 was observed compared to the HA-treated control group (G2). On the other hand, in the EGF-treated group (G5), a decrease in MMP1 and MMP2 was observed compared to the HA-treated control group (G2), but a statistically significant difference was confirmed only in MMP2, and the effect was limited compared to the TDCA-treated group (Figs. 9 and 10).
[0162] In addition, a significant increase in MMP 9 expression was observed in the wounds of the HA-treated control group (G2) compared to the normal control group (G1). The TDCA-treated groups (G3, G4) showed a distinct decrease in MMP 9 expression compared to the HA-treated control group (G2). The EGF-treated group (G5) also showed a lower level of MMP 9 expression than the HA-treated control group (G2), but the degree of decrease was found to be smaller than that of the TDCA-treated groups (G3, G4) (Fig. 11).
[0163] From these results, it is suggested that the TDCA-containing composition of the present invention can be effectively used to improve the tissue remodeling environment and promote wound healing by regulating the excessive activation of MMP-family enzymes in a diabetic foot ulcer model.
[0164]
[0165] Example 8: Confirmation of the effect of normalizing the ECM degradation-production balance in DFU wounds through the restoration of MMP inhibitor TIMP-3 and TIMP-1 expression following TDCA administration in a DFU animal model
[0166] To evaluate the expression of the MMP inhibitor TIMP at the wound site, immunofluorescence staining was performed on the prepared wound sections using an anti-TIMP 1 antibody (bs 4600R, Bioss; 1:50, rabbit) or an anti-TIMP 3 antibody (NBP2 29478, Novus; 1:50, rabbit) as the primary antibody. Subsequently, an Alexa Fluor 546 conjugated anti-rabbit secondary antibody (A10040; 1:100) was applied, and the nuclei were counterstained with DAPI.
[0167] The expression levels of TIMP 1 and TIMP 3 were calculated as mean fluorescence intensity (MFI) within the wound site using ImageJ software. The region corresponding to TIMP 1 or TIMP 3 among the red fluorescence signals obtained from Alexa Fluor 546 was set as the ROI, and the MFI value of each segment was normalized as a percentage (%) relative to the mean value of the DFU + Vehicle group to evaluate the difference between groups; Figures 12 and 13 are graphs showing this quantitatively.
[0168] As a result of the experiment, TIMP3 expression was higher in normal control (G1) wounds than in HA-treated control (G2) wounds, and TIMP3 levels increased in TDCA-treated groups (G3, G4) compared to HA-treated control (G2). Although TIMP3 expression also increased slightly in the EGF-treated group (G5), there was no statistically significant difference compared to the HA-treated control (G2), and a significant increase in TIMP3 levels compared to the HA-treated control (G2) was confirmed only in the 1% TDCA-treated group (G4) (p < 0.05, Fig. 12).
[0169] In addition, the TIMP 1 expression intensity in the normal control group (G1) wound was higher than that of the HA-treated control group (G2), and the TIMP 1 levels in the TDCA-treated groups (G3, G4) also increased significantly compared to the HA-treated control group (G2). An increase in TIMP 1 expression was also observed in the EGF-treated group (G5), but the level was found to be lower than that of the 1% TDCA-treated group (G4) (Fig. 13).
[0170] From these results, it is suggested that the TDCA-containing composition of the present invention can be effectively used to regulate extracellular matrix degradation and promote wound healing by improving the imbalance of the MMP / TIMP axis in a diabetic foot ulcer model.
[0171]
[0172] Example 9: Confirmation of the inhibitory effect of TDCA administration on the expression of inflammatory cytokines IL-1β and IL-18 in a DFU animal model
[0173] To evaluate the expression levels of inflammatory cytokines at the wound site, wound tissues were collected from each group on day 10 after wound induction. The collected wound tissues were homogenized in a lysis buffer containing Halt™ Protease and Phosphatase Inhibitor Cocktail (100X; 78442, Thermo Fisher Scientific) added to T PER™ Tissue Protein Extraction Reagent (78510, Thermo Fisher Scientific). The homogenized tissue solution was centrifuged to remove cells and tissue debris, and the supernatant was recovered for protein analysis.
[0174] The protein concentrations of IL 1β (DY401, R&D Systems) and IL 18 (DY7625 05, R&D Systems) were quantified using ELISA kits corresponding to each cytokine according to the manufacturer's instructions. The absorbance values obtained after ELISA analysis were converted into concentrations by applying them to a standard curve, and Figure 14 is a graph showing this quantitatively.
[0175] As a result of the experiment, a decrease in the concentrations of IL 1β and IL 18 was observed in the TDCA-treated groups (G3, G4) compared to the HA-treated DFU control group (G2), and in particular, the IL 1β concentration in the 0.5% TDCA-treated group (G3) was statistically significantly lower than that of the HA-treated DFU control group (G2) (p < 0.05, Fig. 14 A). The IL 18 concentration in the 1% TDCA-treated group (G4) showed a significant decrease compared to the HA-treated DFU control group (G2) (p < 0.05, Fig. 14 B). Meanwhile, the EGF-treated group (G5) showed lower levels of IL 1β and IL 18 expression compared to the HA-treated DFU control group (G2), but the degree of decrease was similar to or slightly smaller than that of the TDCA-treated groups (G3, G4).
[0176] From these results, it is suggested that the TDCA-containing composition of the present invention can be effectively used to alleviate chronic inflammatory responses at the wound site by suppressing the overexpression of inflammatory cytokines such as IL 1β and IL 18 in a diabetic foot ulcer model, and to create a microenvironment favorable for wound healing and promote tissue regeneration.
[0177]
[0178] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
1. A pharmaceutical composition for the prevention or treatment of diabetic foot disease comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
2. A pharmaceutical composition according to claim 1, characterized in that the taurodeoxycholic acid is a compound represented by the following chemical formula 2: [Chemical Formula 2] 3. A pharmaceutical composition according to claim 1, wherein the salt is one or more salts selected from the group consisting of hydrochloride, sulfate, phosphate, mesylate, malate, maleate, mesylate, besylate, hydrogen sulfate, oxalate, fumarate, tartarate, citrate, succinate, and acetate.
4. A pharmaceutical composition according to claim 1, further comprising hyaluronic acid or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition according to claim 1, wherein the diabetic foot disease is selected from the group consisting of athlete's foot, fungal infection, callus, corn, blister, bunion, dry skin, hammertoe, ingrown toenail, plantar wart, diabetic foot edema, diabetic foot pain, and diabetic foot ulcer.
6. A pharmaceutical composition according to claim 1, characterized in that the diabetic foot disease is a diabetic foot ulcer.
7. A topical skin preparation for the prevention or treatment of diabetic foot disease comprising a pharmaceutical composition according to any one of claims 1 to 6.
8. A topical skin preparation according to claim 7, characterized as being any one selected from the group consisting of aqueous liquids, gels, ointments, creams, lotions, pastes, smears, and patches.
9. A food composition for the prevention or improvement of diabetic foot disease comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
10. A cosmetic composition for preventing or improving diabetic foot disease comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
